Responding to and managing multijurisdictional outbreaks of COVID-19 in Canadian industrial worksite/work camp settings.

SETTING: Early in the COVID-19 pandemic, the Public Health Agency of Canada (PHAC) and provincial/territorial (P/T) public health identified the need for a coordinated response to complex multijurisdictional COVID-19 outbreaks. The first large multijurisdictional industrial worksite COVID-19 outbreak highlighted the risk of transmission within these congregate work settings, the risk of transmission to the broader community(ies), and the need to develop setting-specific outbreak response frameworks. INTERVENTION: PHAC assembled a team to provide national outbreak support for multijurisdictional COVID-19 outbreaks in May 2020. The COVID-19 Outbreak Response Unit (ORU) worked with P/T partners to develop guiding principles for outbreak response and outbreak investigation processes, guidance documents, and investigation tools (e.g., minimum data elements and questionnaires). OUTCOMES: The ORU, P/T partners, and onsite industrial worksite health and safety staff leveraged outbreak investigation guidelines, industrial worksite outbreak process documents (including minimum data elements), and enhanced case questionnaires to respond to multiple COVID-19 outbreak investigations in industrial worksites. Clear roles/responsibilities and processes, along with standardized data, allowed for more efficient outbreak investigations and earlier implementation of mitigation measures. IMPLICATIONS: Multijurisdictional COVID-19 outbreaks highlighted the importance of public health collaboration with industry partners onsite. The assembly of a national outbreak response team was important to facilitate information sharing and provide technical support. Lessons learned and recommendations on outbreak preparation, detection, management, and communication are included to enhance a response framework applicable to future emerging or re-emerging pathogens with epidemic and/or pandemic potential.

RéSUMé: CONTEXTE: Au début de la pandémie de COVID-19, l'Agence de la santé publique du Canada (ASPC) et les autorités provinciales/territoriales de santé publique ont reconnu la nécessité d'une réponse coordonnée en cas d'éclosions complexes multi-juridictionnelles de COVID-19. La première grande éclosion multi-juridictionnelle de COVID-19 dans un chantier industriel a mis en évidence le risque de transmission dans ces milieux de travail collectifs, le risque de transmission à l'ensemble de la (des) communauté(s) et la nécessité d'élaborer des cadres d'intervention en cas d'éclosion spécifiques aux types de milieux. INTERVENTION: L'ASPC a formé une équipe chargée de soutenir la réponse nationale contre les éclosions multi-juridictionnelles de COVID-19 en mai 2020. L'Unité d'intervention en cas d'éclosion (UIE) de COVID-19 a collaboré avec des partenaires provinciaux et territoriaux pour élaborer des principes de référence pour la lutte contre les éclosions de COVID-19 et des processus d'enquête sur les éclosions, des documents d'orientation et des outils d'enquête (p.ex. des éléments de données minimales et des questionnaires). RéSULTATS: L'UIE, les provinces et territoires et le personnel chargé de la santé et sécurité du travail sur le site se sont appuyés sur des principes de référence aux enquêtes sur les éclosions, les documents de processus d'enquête sur les éclosions dans les sites industriels, y compris les éléments de données minimales et le questionnaire détaillé sur les cas, pour répondre à multiples enquêtes d'éclosions de COVID-19 dans les sites industriels. Des rôles/responsabilités et des processus clairs, ainsi que des données standardisées, ont permis de mener des enquêtes plus efficaces sur les éclosions et de mettre en œuvre plus rapidement des mesures d'atténuation. IMPLICATIONS: Les éclosions multi-juridictionnelles de COVID-19 ont mis en évidence l'importance de la collaboration entre les autorités de santé publique et les partenaires industriels sur site. La constitution d'une équipe nationale d'intervention en cas d'éclosion a été importante pour faciliter le partage des informations et fournir un soutien technique. Les connaissances acquises et les recommandations sur la préparation, la détection, la gestion et la communication des éclosions sont incluses afin d'améliorer le cadre de réponse aux futurs agents pathogènes émergents ou ré-émergents ayant un potentiel épidémique et/ou pandémique.

Invasive group A streptococcal (iGAS) surveillance in Island Health, British Columbia, 2022.

Background: Invasive group A streptococcal disease (iGAS) is caused by Streptococcus pyogenes group A bacteria. In 2022, multiple disease alerts for iGAS in the Island Health region, in the context of increased infections in the paediatric population in Europe and the United States, prompted further investigation into local trends. This surveillance study summarizes epidemiological trends of iGAS in the region covered by Island Health, a regional health authority in British Columbia, in 2022. Methods: In British Columbia, iGAS is a reportable disease; all confirmed cases are reported to the regional authority and the provincial health authority (BC Centre for Disease Control). Island Health's iGAS surveillance system is passive and collects information on cases that are identified through laboratory testing. Surveillance data were summarized for 2022 and compared with historical data from 2017-2021. Results: In 2022, the incidence rate was 11.4 cases per 100,000 population (n=101), the highest observed rate in the last six years. The median age of cases was 53 years, with a range of 0-96 years, and 64% of cases were male. The highest risk of infection was reported in men 40-59 years of age, with an incidence rate of 21.3 cases per 100,000 population. The most common emm types were emm92 (n=14), emm49 (n=13), and emm83 (n=12). Overall, 85% (n=86) of cases were hospitalized, 21% (n=21) were admitted to the intensive care unit, and 6% (n=6) died. Conclusion: This study highlights that the incidence of iGAS in the Island Health region continued to increase throughout the coronavirus disease 2019 (COVID-19) pandemic, reaching its highest annual rate in 2022. In contrast to reports from Europe and the United States, there was no notable increase in infections in the paediatric population. Given the sustained increase in iGAS activity, continued monitoring and description of the epidemiology of these cases on a regular basis is imperative.

Exploring the geographical distribution of human cryptosporidiosis in Southern Ontario from 2011 to 2014.

Cryptosporidium is a protozoan parasite of increasing global public health concern because of its ability to cause disease in both humans and animals through contaminated food and water supplies. In Canada, most human cryptosporidiosis cases are due to Cryptosporidium hominis; however, the presence of zoonotic Cryptosporidium parvum has been observed. Since 2005, the incidence of cryptosporidiosis in Ontario has been consistently higher than the national average; however, it is not understood why, suggesting an incomplete understanding of the pathogen's ecology, epidemiology and transmission pathways. The goal of this study was to explore the spatial distribution of human cryptosporidiosis across the 29 Public Health Unit (PHU) areas of Southern Ontario from 2011 to 2014. Surveillance data on human cryptosporidiosis were obtained from Public Health Ontario. Choropleth and isopleth maps were used to display the distribution of incidence rates of human cryptosporidiosis. High-rate clusters of human cryptosporidiosis were identified. Poisson and spatial Poisson regression models were used to determine the relationship between the incidence of human cryptosporidiosis, cattle density and the smoothed farm-level prevalence of bovine cryptosporidiosis at the PHU level. The annual incidence of reported human cryptosporidiosis in Southern Ontario ranged from 1.62 (95% CI: 1.41-1.86) to 1.82 (95%CI: 1.60-2.06) cases per 100,000 population, with an overall cumulative incidence of 6.91 (95%CI: 6.47-7.39) cases per 100,000 for the 4-year study period. High-risk clusters of human cryptosporidiosis were identified in each year. The relative risk for the clusters ranged from 2.03 (95% CI: 1.63-2.55) to 6.87 (95% CI: 5.07-9.30). A relationship was found between the incidence of cryptosporidiosis and dairy cattle density. Based on this study, the Central West region would be an ideal ecological system to conduct further targeted surveillance to identify factors that may be contributing to the higher burden of cryptosporidiosis in the human and bovine populations in the region.

National Influenza Annual Report, Canada, 2020-2021, in the global context.

During the 2020-2021 Canadian influenza season, no community circulation of influenza occurred. Only 69 positive detections of influenza were reported, and influenza percent positivity did not exceed 0.1%. Influenza indicators were at historical lows compared with the previous six seasons, with no laboratory-confirmed influenza outbreaks or severe outcomes being reported by any of the provinces and territories. Globally, influenza circulation was at historically low levels in both the Northern and the Southern Hemispheres. The decreased influenza activity seen in Canada and globally is concurrent with the implementation of non-pharmaceutical public health measures to mitigate the spread of the coronavirus disease 2019 (COVID-19). Although it is difficult to predict when influenza will begin to re-circulate, given the increased COVID-19 vaccination and the relaxation of public health measures, an influenza resurgence can be expected and may be more severe or intense than recent seasons. Influenza vaccination, along with non-pharmaceutical public health measures, continues to remain the best method to prevent the spread and impact of influenza. Public health authorities need to remain vigilant, maintain surveillance and continue to plan for heightened seasonal influenza circulation.

Impact of nonpharmaceutical interventions on laboratory detections of influenza A and B in Canada.

BACKGROUND: The first coronavirus disease 2019 (COVID-19) case was reported in Canada on January 25, 2020. In response to the imminent outbreak, many provincial and territorial health authorities implemented nonpharmaceutical public health measures to curb the spread of disease. "Social distancing" measures included restrictions on group gatherings; cancellation of sports, cultural and religious events and gatherings; recommended physical distancing between people; school and daycare closures; reductions in non-essential services; and closures of businesses. OBJECTIVES: To evaluate the impact of the combined nonpharmaceutical interventions imposed in March 2020 on influenza A and B epidemiology by comparing national laboratory surveillance data from the intervention period with 9-year historical influenza season control data. METHODS: We obtained epidemiologic data on laboratory influenza A and B detections and test volumes from the Canadian national influenza surveillance system for the epidemiologic period December 29, 2019 (epidemiologic week 1) through May 2, 2020 (epidemiologic week 18). COVID-19-related social distancing measures were implemented in Canada from epidemiologic week 10 of this period. We compared influenza A and B laboratory detections and test volumes and trends in detection during the 2019-20 influenza season with those of the previous nine influenza seasons for evidence of changes in epidemiologic trends. RESULTS: While influenza detections the week prior to the implementation of social distancing measures did not differ statistically from the previous nine seasons, a steep decline in positivity occurred between epidemiologic weeks 10 and 14 (March 8-April 4, 2020). Both the percent positive on week 14 (p≤0.001) and rate of decline between weeks 10 and 14 (p=0.003) were significantly different from mean historical data. CONCLUSION: The data show a dramatic decrease in influenza A and B laboratory detections concurrent with social distancing measures and nonpharmaceutical interventions in Canada. The impact of these measures on influenza transmission may be generalizable to other respiratory viral illnesses during the study period, including COVID-19.

National influenza mid-season report, 2020-2021.

Canada's national influenza season typically starts in the latter half of November (week 47) and is defined as the week when at least 5% of influenza tests are positive and a minimum of 15 positive tests are observed. As of December 12, 2020 (week 50), the 2020-2021 influenza season had not begun. Only 47 laboratory-confirmed influenza detections were reported from August 23 to December 12, 2020; an unprecedentedly low number, despite higher than usual levels of influenza testing. Of this small number of detections, 64% were influenza A and 36% were influenza B. Influenza activity in Canada was at historically low levels compared with the previous five seasons. Provinces and territories reported no influenza-associated adult hospitalizations. Fewer than five hospitalizations were reported by the paediatric sentinel hospitalization network. With little influenza circulating, the National Microbiology Laboratory had not yet received samples of influenza viruses collected during the 2020-2021 season for strain characterization or antiviral resistance testing. The assessment of influenza vaccine effectiveness, typically available in mid-March, is expected to be similarly limited if low seasonal influenza circulation persists. Nevertheless, Canada's influenza surveillance system remains robust and has pivoted its syndromic, virologic and severe outcomes system components to support coronavirus disease 2019 (COVID-19) surveillance. Despite the COVID-19 pandemic, the threat of influenza epidemics and pandemics persists. It is imperative 1) to maintain surveillance of influenza, 2) to remain alert to unusual or unexpected events and 3) to be prepared to mitigate influenza epidemics when they resurge.

National Influenza Mid-Season Report, 2019-2020.

Canada's national influenza season started in week 47 between November 17 to 23, 2019. Of the 3,762 laboratory-confirmed influenza detections reported from August 25 to December 14, 2019, 61% were influenza A, and of those subtyped, 68% were A(H3N2). Influenza B detections are above average for this time of year. Indicators of influenza activity are within the expected range for this time of year. The majority of hospitalizations reported by provinces and territories have been associated with influenza A(H3N2) (76%), and the greatest proportion have been among adults 65 years and older (40%). Among sentinel pediatric influenza hospitalizations, 55% were associated with influenza B and the majority have been under five years of age (63%). Antigenic and genetic characterization results to date suggest that the majority of circulating A(H3N2) and B viruses are not similar to the virus components recommended for use in the 2019-2020 seasonal influenza vaccines and that the majority of circulating A(H1N1) viruses are similar to the vaccine reference strains.

A Scoping Review of the Evidence for the Medicinal Use of Natural Honey in Animals.

Honey has a history of medicinal use that predates written records. In recent decades, there has been renewed interest in the use of honey in human medicine, particularly for the treatment of burns and other wounds. Several recent systematic reviews in the human literature have demonstrated the efficacy of honey in the treatment of a number of conditions, including burns, wounds and oral mucositis. The goal of this scoping review was to describe the nature and extent of the current body of evidence addressing the medicinal use of natural honey and/or its derivatives in animals. Although the focus of this review was the veterinary literature, all animal species except insects and humans were eligible, including animals used for biomedical research. Electronic databases searched were MEDLINE, CAB Abstracts, AGRICOLA, Web of Science Core Collection, and Web of Science SciELO Citation Index. A total of 397 articles reporting 436 primary research studies were included in this review. The majority of the articles were biomedical research articles (n = 350); fewer veterinary research articles were identified (n = 47). Apart from one systematic review, all biomedical studies were challenge trials. Most veterinary studies were case reports/series (n = 23), followed by challenge trials (n = 18) and controlled trials (n = 8). The animal species examined within veterinary articles consisted primarily of dogs, horses, cats and cattle, whereas the majority of biomedical research articles examined rats and mice. Wound healing was the most common indication examined; other indications examined included the prevention or treatment of gastric ulcers, bacterial and parasitic infections, toxic exposures, metabolic conditions (e.g., diabetes) and neoplasia. The majority of interventions consisted of non-medical grade honey (n = 412/436), followed by medical-grade honey (n = 29/436) and derivatives of natural honey (n = 9/436). With much of the current veterinary literature consisting of case reports and case series, high-quality primary veterinary research in the form of controlled trials or challenge trials is needed to advance this field, as well as to provide sound data for evidence-based assessments of the efficacy of honey in clinical veterinary practise.

Exploring the geographical distribution of cryptosporidiosis in the cattle population of Southern Ontario, Canada, 2011-2014.

Cryptosporidiosis is an infectious disease of relevance to the cattle industry. The southern region of the Canadian province of Ontario is characterised by widespread cattle farming that is a key contributor to the Canadian dairy industry. Given Ontario's key role in the Canadian dairy industry and the potential impact that cryptosporidiosis can have on cattle operations, identifying areas of increased risk for bovine cryptosporidiosis is important. The primary goal of this study was to explore the distribution of bovine cryptosporidiosis, across the geographical areas served by the 29 Public Health Units (PHUs) of Southern Ontario, in the period 2011-2014. Laboratory data on bovine cryptosporidiosis were collected from the Animal Health Laboratory at the University of Guelph, Canada. Using veterinary clinic locations as a proxy for farm location, choropleth and isopleth maps were produced. Highrisk clusters of bovine cryptosporidiosis were identified using the flexible spatial scan test. Assessment of the potential for spatial misclassification bias resulting from a proxy location variable was conducted. The overall raw farm-level prevalence of bovine cryptosporidiosis was 45% [95% confidence interval, CI: 42%-48%]. A cluster was identified in the central-west region of Southern Ontario (relative risk 1.30 [95% CI: 1.07-1.54, P=0.026]) meaning that cattle in the areas served by the Bruce-Grey-Owen Sound, Huron, Wellington-Dufferin Guelph and Waterloo PHUs were at a higher risk for infection. Given that this area is known for having a high-density of dairy cattle, it should be considered as a target for further surveillance.

Burden of influenza-associated respiratory hospitalizations in the Americas, 2010-2015.

BACKGROUND: Despite having influenza vaccination policies and programs, countries in the Americas underutilize seasonal influenza vaccine, in part because of insufficient evidence about severe influenza burden. We aimed to estimate the annual burden of influenza-associated respiratory hospitalizations in the Americas. METHODS: Thirty-five countries in the Americas with national influenza surveillance were invited to provide monthly laboratory data and hospital discharges for respiratory illness (International Classification of Diseases 10th edition J codes 0-99) during 2010-2015. In three age-strata (<5, 5-64, and ≥65 years), we estimated the influenza-associated hospitalizations rate by multiplying the monthly number of respiratory hospitalizations by the monthly proportion of influenza-positive samples and dividing by the census population. We used random effects meta-analyses to pool age-group specific rates and extrapolated to countries that did not contribute data, using pooled rates stratified by age group and country characteristics found to be associated with rates. RESULTS: Sixteen of 35 countries (46%) contributed primary data to the analyses, representing 79% of the America's population. The average pooled rate of influenza-associated respiratory hospitalization was 90/100,000 population (95% confidence interval 61-132) among children aged <5 years, 21/100,000 population (13-32) among persons aged 5-64 years, and 141/100,000 population (95-211) among persons aged ≥65 years. We estimated the average annual number of influenza-associated respiratory hospitalizations in the Americas to be 772,000 (95% credible interval 716,000-829,000). CONCLUSIONS: Influenza-associated respiratory hospitalizations impose a heavy burden on health systems in the Americas. Countries in the Americas should use this information to justify investments in seasonal influenza vaccination-especially among young children and the elderly.

Non-antibiotic approaches for disease prevention and control in beef and veal production: a scoping review.

Livestock producers are encouraged to reduce the use of antibiotics belonging to classes of medical importance to humans. We conducted a scoping review on non-antibiotic interventions in the form of products or management practices that could potentially reduce the need for antibiotics in beef and veal animals living under intensive production conditions. Our objectives were to systematically describe the research on this broad topic, identify specific topics that could feasibly support systematic reviews, and identify knowledge gaps. Multiple databases were searched. Two reviewers independently screened and charted the data. From the 13,598 articles screened, 722 relevant articles were charted. The number of relevant articles increased steadily from 1990. The Western European research was dominated by veal production studies whereas the North American research was dominated by beef production studies. The interventions and outcomes measured were diverse. The four most frequent interventions included non-antibiotic feed additives, vaccinations, breed type, and feed type. The four most frequent outcomes were indices of immunity, non-specific morbidity, respiratory disease, and mortality. There were seven topic areas evaluated in clinical trials that may share enough commonality to support systemic reviews. There was a dearth of studies in which interventions were compared to antibiotic comparison groups.

Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003-2014.

BACKGROUND: A regression-based study design has commonly been used to estimate the influenza burden; however, these estimates are not timely and many countries lack sufficient virological data. Alternative approaches that would permit a timelier assessment of the burden, including a sentinel surveillance approach recommended by the World Health Organization (WHO), have been proposed. We aimed to estimate the hospitalization burden attributable to influenza, respiratory syncytial virus (RSV), and other respiratory viruses (ORV) and to assess both the completeness of viral identification among respiratory inpatients in Canada and the implications of adopting other approaches. METHODS: Respiratory inpatient records were extracted from the Canadian Discharge Abstract Database from 2003 to 2014. A regression model was used to estimate excess respiratory hospitalizations attributable to influenza, RSV, and ORV by age group and diagnostic category and compare these estimates with the number with a respiratory viral identification. RESULTS: An estimated 33 (95% CI: 29, 38), 27 (95% CI: 22, 33), and 27 (95% CI: 18, 36) hospitalizations per 100 000 population per year were attributed to influenza, RSV, and ORV, respectively. An influenza virus was identified in an estimated 78% (95% CI: 75, 81) and 17% (95% CI: 15, 21) of respiratory hospitalizations attributed to influenza for children and adults, respectively, and 75% of influenza-attributed hospitalizations had an ARI diagnosis. CONCLUSIONS: Hospitalization rates with respiratory viral identification still underestimate the burden. Approaches based on acute respiratory case definitions will likely underestimate the burden as well, although each proposed method should be compared with regression-based estimates of influenza-attributed burden as a way of assessing their validity.